1481 related articles for article (PubMed ID: 28844335)
21. The Role of Neprilysin Inhibitors in Cardiovascular Disease.
Mills J; Vardeny O
Curr Heart Fail Rep; 2015 Dec; 12(6):389-94. PubMed ID: 26466607
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
Chin KL; Zomer E; Wang BH; Liew D
Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
[TBL] [Abstract][Full Text] [Related]
23. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Nguyen E; Weeda ER; White CM
J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
[TBL] [Abstract][Full Text] [Related]
24. The safety of sacubitril-valsartan for the treatment of chronic heart failure.
Tyler JM; Teerlink JR
Expert Opin Drug Saf; 2017 Feb; 16(2):257-263. PubMed ID: 28060547
[TBL] [Abstract][Full Text] [Related]
25. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
Curtain JP; Adamson C; Docherty KF; Jhund PS; Desai AS; Lefkowitz MP; Rizkala AR; Rouleau JL; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJV
JACC Heart Fail; 2023 Jul; 11(7):749-759. PubMed ID: 37407154
[TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
28. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
Balmforth C; Simpson J; Shen L; Jhund PS; Lefkowitz M; Rizkala AR; Rouleau JL; Shi V; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
JACC Heart Fail; 2019 Jun; 7(6):457-465. PubMed ID: 31078482
[TBL] [Abstract][Full Text] [Related]
29. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
30. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology.
Perrone-Filardi P; Paolillo S; Agostoni P; Basile C; Basso C; Barillà F; Correale M; Curcio A; Mancone M; Merlo M; Metra M; Muscoli S; Nodari S; Palazzuoli A; Pedrinelli R; Pontremoli R; Senni M; Volpe M; Indolfi C; Sinagra G
Eur J Intern Med; 2022 Aug; 102():8-16. PubMed ID: 35469709
[TBL] [Abstract][Full Text] [Related]
31. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Kario K
Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
[TBL] [Abstract][Full Text] [Related]
32. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
33. Sacubitril/valsartan: A practical guide.
Fonseca C; Brito D; Ferreira J; Franco F; Morais J; Silva Cardoso J;
Rev Port Cardiol (Engl Ed); 2019 May; 38(5):309-313. PubMed ID: 30679005
[TBL] [Abstract][Full Text] [Related]
34. Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea.
Park SK; Hong SH; Kim H; Kim S; Lee EK
Clin Ther; 2019 Jun; 41(6):1066-1079. PubMed ID: 31101372
[TBL] [Abstract][Full Text] [Related]
35. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
Dargad RR; Prajapati MR; Dargad RR; Parekh JD
Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S102-S110. PubMed ID: 30122239
[TBL] [Abstract][Full Text] [Related]
36. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.
Lee WC; Liao TW; Chen TY; Fang HY; Fang YN; Chen HC; Lin YS; Chang SH; Chen MC
Cardiovasc Drugs Ther; 2024 Jun; 38(3):505-515. PubMed ID: 36609948
[TBL] [Abstract][Full Text] [Related]
37. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Vilela-Martin JF
Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
[TBL] [Abstract][Full Text] [Related]
38. [A novel agent in the treatment of heart failure with depressed systolic function].
Duarte Vera YC; Cáceres Vinueza SV; Daher Nader JE; Lara Terán JF
Arch Cardiol Mex; 2018; 88(4):287-297. PubMed ID: 29501368
[TBL] [Abstract][Full Text] [Related]
39. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
Cannon JA; Shen L; Jhund PS; Kristensen SL; Køber L; Chen F; Gong J; Lefkowitz MP; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Eur J Heart Fail; 2017 Jan; 19(1):129-137. PubMed ID: 27868321
[TBL] [Abstract][Full Text] [Related]
40. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]